


Recent advances in the therapeutic potential phytochemicals in managing diabetes

Muhammad Mubarak Dahiru^{1*} 

1. Department of Science Laboratory Technology, School of Science and Technology, Adamawa State Polytechnic, Yola

* Correspondence: Muhammad Mubarak Dahiru, Department of Science Laboratory Technology, School of Science and Technology, Adamawa State Polytechnic, Yola. Email: mubaraq93@gmail.com

Article History

Received: 24 January 2023
Received in revised form: 13 May 2023
Accepted: 13 June 2023
Published online: 15 July 2023
DOI: [10.29252/JCBR.7.1.13](https://doi.org/10.29252/JCBR.7.1.13)

Keywords

Anti-diabetic
Diabetes mellitus
Medicinal plants
Phytochemicals
Therapeutic roles

Article Type: Review Article



Abstract

Diabetes and diabetic complications have been a global menace for a long time, putting a heavy burden on an individual, the health sector, and governments. Diabetic complications attributed to persistent hyperglycemia create a challenge in managing diabetes, considering the nature of the disease as a group of metabolic disorders. Various phytochemicals target different metabolic pathways and molecules through different mechanisms of action, acting individually or synergistically to achieve therapeutic goals. Phytochemicals such as alkaloids, saponins, glycosides, terpenoids, and flavonoids were reported to exert different anti-diabetic effects, including anti-hyperglycemic, anti-hyperlipidemic, anti-inflammatory, antioxidant, and insulinotropic activities. The present review focused on the recent advances in the therapeutic potentials of phytochemicals in managing diabetes and diabetic complications, emphasizing their *in vitro* and *in vivo* studies.

Highlights

What is current knowledge?

Phytochemicals from medicinal plants attenuate diabetic symptoms *via* different mechanisms of action including anti-hyperglycemic, anti-hyperlipidemia, anti-inflammatory, and antioxidant effects. However, attaining glycemic control and treatment of diabetic complications still remains a challenge.

What is new here?

Some of the phytochemicals reported here might be sources for the development of novel anti-diabetic drugs.

Introduction

Diabetes is a group of metabolic disorders that have gone beyond glycemic control requiring multiple approaches to manage and emerging as a global menace leading to reduced life expectancy and complications that might be fatal (1). This disease requires prevention strategies for acute complications and decreasing the risks associated with chronic disease complications. Clinical diagnosis of diabetes may be achieved by testing for plasma glucose levels using two approaches; fasting plasma glucose (FPG) value or 75-g oral glucose tolerance test of (OGTT) 2h plasma glucose (PG) value or hemoglobin test (HbA1c) approach (2). For the FPG approach, an FPG level of ≥ 126 mg/dL (7.0 mmol/L) for an individual with at least eight post-calorie intakes signifies diabetes, while in the OGTT approach, a PG level of ≥ 200 mg/dL (11.1 mmol/L) after 2h of the OGTT signifies diabetes. When utilizing the HbA1c criteria, an HbA1c level $\geq 6.5\%$ is considered an indicator of diabetes. However, for an individual manifesting classic symptoms of unstable glycemic control, a random glucose test approach with PG ≥ 200 mg/dL (11.1 mmol/L) is regarded as the diagnosis for diabetes mellitus (DM). Diabetes can be classified into type 1 DM, type 2 DM, gestational DM, and other diabetes conditions manifesting as a result of other causes (3).

Worldwide, the number of people with diabetes has risen to half a billion, up to 10.5% of the world's adult population (4). In 2021, young adults between the ages of 20-29 rank up to 10.5% of the prevalence of DM, estimated to be up to 536.6 million. This figure is projected to rise to 12.2% by 2045, including 783.2 million people (4). The prevalence in both genders was similar in 2021, though higher within 75-79 years. A higher prevalence was in urban areas (12.1%) and high-income countries (11.1%) than the rural areas (8.3%) and low-income

countries (5.5%), with an expected projection within middle-income countries than both high- and low-income countries (4). This represents a huge burden on the healthcare system and government expenditures on a country's health, especially considering the expected rise in cases. In 2021, the world expenditure on diabetes-related expenses was estimated to be 966 billion USD, with an expected rise of up to 1.054 billion USD by 2045 (4). The necessity for alternative medical options that are inexpensive and accessible, such as plant-based phytochemicals, is particularly vital for individuals residing in rural areas with inadequate healthcare facilities.

Different strategies exist for managing diabetes, with exercise being the recommended practice. Anti-diabetic agents used in diabetic management range from insulin therapy to anti-diabetic drugs used singly or combined therapies and are often associated with some side effects and high costs (5). The nature of diabetes as a multiple disorder makes it a target for different therapy. However, long-term continuous use of anti-diabetic agents might lead to further complications due to disturbance of metabolic pathways (5). Medicinal plants are often preferred as alternatives for managing diabetes, especially for people in low-income countries and rural dwellers due to availability and low cost with a synergistic mode of action. These plants comprise phytochemicals such as alkaloids, saponins, and flavonoids attributed to different pharmacological activities to achieve glycemic control, evidenced by their use in traditional folkloric medicine (6). With the rising cost of treatment of diabetes worldwide, which is projected to rise more by 2045, and the obvious burden on government expenditures on healthcare, there is continuous exploitation of natural cheap and affordable sources for novel therapeutics, especially in the low-income countries where there is poor or no access to proper healthcare facilities. Thus, the present review explores the recent advances in the therapeutic roles of phytochemicals in managing diabetes.

Alkaloids

Alkaloids are naturally occurring compounds composed of one or more nitrogen atoms, usually within the compound's ring structure, giving it alkaline properties. These compounds are widely found in plants and classified into different classes, including indoles, quinolines, and isoquinolines (7). These compounds are associated with several pharmacological activities, and a notable example is morphine attributed with clinical applications. Although alkaloids are used as pain relievers, their uses are somehow limited due to addiction. Other clinical applications of these compounds include cardiac stimulants (morphine), muscle relaxants (tubocurarine), anticancer (vincristine and vinblastine), and ephedrine employed in bronchial asthma and the common cold (7). Alkaloids in many medicinal plants were attributed to their pharmacological activities. Thus, their

use in folkloric medicine includes anti-microbial, anti-diabetic, anticancer, analgesic, and sedatives (8-10). Alkaloids were previously reported to exert anti-diabetic effects via different modes of action, such as stimulating insulin secretion, inhibiting digestive enzymes and forming advanced glycation end products (AGEs), and promoting glucose uptake by cells (11).

The quinoline alkaloid berberine from the roots and stem bark of *Tinospora cordifolia* was reported to exhibit hypoglycemic properties by inhibiting sucrose activity in Caco-2 cells after 72h of preincubation via decreased glucose absorption in the intestinal epithelium and blocking α -glucosidase (12). Oral administration of hypoglycemic alkaloids catharanthine, vindoline, and vindolinine from ethanol extract of *Catharanthus roseus* combined with sitagliptin showed hypoglycemic effects with significant anti-diabetic activities in hyperlipidemic and diabetic mice (13). 5-hydroxymethylfurfural identified from *Lobelia chinensis* was reported to exert anti-diabetic activity in silico by attenuating insulin resistance via acting on GSK3B, TNF, MAPK1, and INSR, DPP4, and GSK3B regulating insulin resistance (14). Schulzeines A, B, and C, three iso-quinoline alkaloids from *Penares schulzei*, exerted hypoglycemic properties in vitro via α -glucosidase suppression (15). Another alkaloid palmitine was reported to inhibit the key enzymes of carbohydrate digestion in silico; α -amylase and α -glucosidase. Studies on palmitine via molecular docking revealed that palmitine exerts its activity by competitive inhibition (16).

Carbazole alkaloids extracted from *Murraya koenigii* L. and Vindogentianine from *Catharanthus roseus* inhibited α -glucosidase when p-nitrophenyl glucopyranoside was employed as a substrate (17, 18). In streptozotocin-induced (STZ-induced) diabetic rat models, holaphylline and sarcovagine D (steroidal alkaloids) exerted hypoglycemic potential with minimized diabetic complications (19). Similarly, O-methylmurrayamine A and koenidine exerted more hypoglycemic effects than metformin in STZ-induced diabetic rats (20). Alkaloids also exert pharmacological activities against aldose reductase, a key enzyme of glucose metabolism associated with diabetic complications due to the accumulation of its product (sorbitol) and metabolite (fructose). Isoquinoline alkaloids from *Tinospora cordifolia* stem the aldose reductase activity from the lens of male Wistar albino rats (21). Canthinone alkaloids exerted inhibitory activity using p-nitrophenyl phosphate against protein tyrosine phosphatase-1B (PTP1B), an enzyme present in several tissues playing an active role in multiple signal transduction pathways (22, 23). Inhibition of PTP1B promotes glucose intake by enhancing insulin receptors and phosphorylation insulin of receptors 1 and 2 (23). Similarly, via a substrate-based mechanism, Vindogentianine from *Catharanthus roseus* inhibited protein tyrosine phosphatase-1B (18). Another alkaloid, lupanine from the *Lupinus* species, enhances insulin secretion via glucose-dependent inhibition of ATP-sensitive potassium channels current and enhances gene expression for insulin secretion in rats (24).

Trigonelline was reported to enhance insulin sensitivity in high-fat-fed and low-dose streptozotocin-induced diabetic rats (25). Benzylisoquinoline alkaloids from *Ocotea paranapiacabensis* inhibited the formation of AGEs responsible for diabetic complications such as nephropathy, retinopathy, and neuropathy via in vitro bovine serum albumin/methylglyoxal reagent assay (26). Diketopiperazine isolated from *Aspergillus* sp. 16-5c exerted in vitro inhibitory properties against α -glucosidase without inhibiting PTP1B (27). The fumiquinazoline alkaloids scequinadolines D isolated from *Scedosporium apiospermum* exert its anti-diabetic activity in vitro by enhancing insulin sensitivity in adipocytes promoting triglyceride accumulation in 3T3-L1 cells by stimulating the expression of PPAR γ , AMPK α , C/EBP α , LXR α , SCD-1, and FABP4, thereby activating the PPAR γ pathway (28). Eurocristatine isolated from *Eurotium cristatum* exhibited remarkable hypoglycemic activity and improved glucose tolerance, insulin release, and sensitivity and mitigated diabetic liver toxicity in db/db mice (29). Furthermore, in vitro study showed decreased insulin resistance via enhanced glucose uptake and consumption with increased glycogen storage in HepG2 cells subjected to high glucose with enhanced glycogen synthesis (29).

Hernandezine, a natural alkaloid, is an anti-diabetic potential in mouse models via indirect activation of AMP-activated protein kinase by suppressing its dephosphorylation. Additionally, oral administration of hernandezine reduced body weight and hyperglycemia by increasing glucose uptake and decreasing lipogenesis (30). The intestinal oxidative metabolite of berberine, oxyberberine, showed promising potential in alleviating diabetic symptoms by decreasing blood glucose levels, healing pancreatic damage, and exerting anti-inflammatory and antioxidant properties in STZ-induced diabetic rats (31). Furthermore, the intestinal oxidative metabolite oxyberberine exerted a better anti-diabetic activity than berberine by up-regulating the expression mRNA of Nrf2 and PI3K/Akt signaling pathways of the pancreas (31). Coumarin compounds were previously reported to exert anti-diabetic activities both in vitro and in vivo in animal models (32). The anti-diabetic effects of some alkaloids are summarized in Table 1, while their structures are presented in Figure 1.

Saponins

Saponins comprise a group of amphiphilic glycosides and steroid terpenes with diverse structural components consisting of a carbohydrate moiety and aglycones originating from plant cells and some marine organisms (33). The diverse structural nature of saponins has been attributed to the various biological and pharmacological effects observed in traditional medicine. Saponins are

Table 1: Anti-diabetic alkaloids

Alkaloids	Anti-diabetic action	Effect
Berberine	Anti-hyperglycemic (12)	<i>In vitro</i>
Catharanthine	Anti-hyperglycemic (113)	<i>In vivo</i> (rats)
Vindoline	Anti-hyperglycemic (114)	<i>In vivo</i> (rats)
Vindolinine	Anti-hyperglycemic (113)	<i>In vivo</i> (rats)
5-hydroxymethylfurfural	Regulate insulin and attenuate insulin resistance (14)	<i>In silico</i>
Schulzeines	Alpha-glucosidase suppression (15)	<i>In vitro</i>
Palmitine	Alpha-amylase and alpha-glucosidase inhibition (16)	<i>In silico</i>
Carbazole	Alpha-glucosidase inhibition (18)	<i>In vitro</i>
Holaphylline	Anti-hyperglycemic (19)	<i>In vitro</i>
Sarcovagine D	Anti-hyperglycemic (19)	<i>In vitro</i>
O-methyl murrayamine A	Anti-hyperglycemic (20)	<i>In vivo</i> (rats)
Koenidine	Anti-hyperglycemic (20)	<i>In vivo</i> (rats)
Vindogentianine	Protein tyrosine phosphatase-1B inhibition (18)	<i>In vitro</i>
Lupanine	Insulinotropic effects (24)	<i>In vivo</i> and (rats)
Trigonelline	Insulinotropic effects (25)	<i>In vivo</i> (rats)
Diketopiperazine	Alpha-glucosidase inhibition (27)	<i>In vitro</i>
Scequinadolines D	Insulinotropic effects (28)	<i>In vitro</i>
Hernandezine	Antihyperglycemic (30)	<i>In vivo</i> (mice)
Oxyberberine	Anti-hyperglycemic, anti-inflammatory, antioxidant (31)	<i>In vivo</i> (rats)




Figure 1. Structures of some anti-diabetic alkaloids

associated with pharmacological effects such as antioxidant, anticancer, anti-microbial, and anti-diabetic effects, thus attracting attention to their exploration of novel therapeutics in clinical and basic research (34-36). Saponins are attributed to various pharmacological activities in managing diabetes. Notably, the blood glucose-lowering potential is exploited in several clinical studies through different mechanisms of action, making them an alternative hypoglycemic agent (37). Saponins exert anti-diabetic effects in the liver, skeletal muscles, pancreas, and gut via concurrent regulations of different signal pathways (38). Administration of saponins from *Momordica charantia* showed improved body weight and glucose tolerance in combined high fat- and STZ-induced diabetic rats with reduced fasting blood glucose levels and improved insulin secretion and sensitivity (39). A significant increase in the activity of antioxidant enzymes and expression of p-IRS-1 (Y612) and p-Akt (S473) was also observed with a decrease in malondialdehyde level and p-IRS-1 (S307) expression (39).

Similarly, administering saponins from *Momordica charantia* to a high-fat diet (HFD) fed C57BLK/6 mice showed improved insulin sensitivity and glucose tolerance (40). Saponin-rich extract of *Tithonia diversifolia* leaves showed a dose-dependent expression and insulin release by up-regulating the expression of Takeda G-protein bile acid receptor 5 (TGR5) in a dose-dependent manner, subsequently releasing GLP1 with decreased HbaC1 level in diabetic model mice

(41). Total saponins extracted by ultrasonic microwave-assisted from *Corni fructus* reduced diabetes in HFD- and STZ-induced diabetic mice by significantly improving glucose and lipid metabolism, reducing oxidative stress, inflammation, hepatic and pancreatic tissue by regulating insulin receptor, glucose transporter 4 (GLUT 4), phosphatidylinositol 3-kinase, and protein kinase B signaling pathways (42). In vitro studies of oleanane-type saponin were observed to be active against α -glucosidase, PTP1B, DPPH, and ATBS assays, potentially a source for the development of anti-diabetic and antioxidant drugs (43). Saponins from *Momordica dioica* exhibited beta cell protective activity and insulinotropic effect in a dose-dependent manner in STZ-induced diabetic rats (44). Similarly, saponins from *Momordica charantia* significantly restored body weight, decreased FBG levels and insulin resistance, and increased phosphorylation of liver adenosine monophosphate-activated protein kinase (p-AMPK)/total protein in STZ-induced diabetic mice. Moreover, the mechanism of action of the above was proposed to be through the AMPK/NF- κ B signaling via activation of AMPK phosphorylation and regulation of energy metabolism (45).

Saponins isolated from *Argania spinosa* significantly decreased blood glucose levels in alloxan-induced diabetic mice, equivalent to 2–4 weeks of metformin treatment (46). Furthermore, these saponins showed a strong anti- α -amylase and α -glucosidase activity in vitro. In another in vitro study, saponins extracted from fruit and seeds of *Cupressus sempervirens* inhibited α -amylase in starch digestion bioassay (47). Gylongiposide I identified in *Gynostemma pentaphyllum* exhibited a glucose-dependent insulinotropic effect by stimulating insulin in high glucose concentration with limited effects at low concentration, making it a candidate for developing novel therapeutic with insulinogenic effect (48). Oral administration of entagenic acid to type 2 diabetic db/db mice significantly decreased post-prandial glucose without significantly affecting body weight. Moreover, improved insulin sensitivity, glucose tolerance, and pathological changes in the pancreatic islets were observed. Additionally, in vitro studies showed an improvement in glucose utilization in a dose-dependent manner with enhanced GLUT4 expression and translocation and AMPK phosphorylation (49). Furostanol saponins from *Asparagus racemosus* reduced the post-prandial glucose level in db/db mice type 2 diabetes model deficient in leptin receptor (50). Furthermore, the AMPK-dependent signaling pathway was activated by the saponins influencing GLUT4 translocation. Additionally, in vivo pharmacological studies demonstrated that these saponins have higher bioavailability and efficacy (50).

Saponins modulated glucose homeostasis via PPAR γ -mediated mechanism in type 2 diabetes hypertensive rat model (51). New Nor-triterpenoid saponins exhibited anti-diabetic properties where two of the four compounds activated peroxisome PPAR- α but not the γ (52). Saponin extract from *Ziziphus Mauritiana* leaves significantly inhibited α -amylase with a strong reduction capacity than ascorbic acid, demonstrating anti-diabetic and antioxidant potential (53). Saponins from *Polygonatum sibiricum* significantly decreased insulin secretion and FBG levels with significant improvement of lipid profile in type 2 diabetes mice (54). Moreover, the gut microbiota and metabolites of the mice were evaluated and analyzed by 16S rDNA sequencing and metabolic profiling revealing a decrease in Firmicutes, Bacteroidetes, and some bacteria genera. At the same time, a great effect was observed on carbohydrate metabolism and amino acid metabolisms (54). Saponins by-products of *Asparagus officinalis* L. in STZ-induced type 2 diabetic rats significantly decreased the fasting serum glucose with an accompanied increase in the hepatic glycogen and improved lipid profile (55). Saponins extracted from *Panax notoginseng* were reported to alleviate insulin resistance in muscles skeletal via regulating GLUT4 expression and IRS1–PI3K–AKT signaling pathway (56). Insulin-induced glucose uptake was increased in the skeletal myoblast cell line, C2C12.

Moreover, blood glucose and serum insulin levels decreased with accompanying glucose and insulin tolerance improvement in KKAY mice. Additionally, the apoptosis and pathological changes of the skeletal muscle cells were reduced with enhanced expression of IRS1 and GLUT4 in C2C12 and KKAY mouse muscle (56). The anti-diabetic effects of some saponins are presented in Table 2, while their structures are shown in Figure 2.




Figure 2. Structures of some antidiabetic saponins

Table 2. Antidiabetic saponins

Saponins	Anti-diabetic action	Effect
Oleanane	Protein tyrosine phosphatase-1B and α -glucosidase inhibition (43)	<i>In vitro</i>
Gylongiposide I	Insulinotropic (48)	<i>In vitro</i>
Entagenic acid	Anti-hyperglycemic and insulinotropic effects (49)	<i>In vitro</i> and <i>In vivo</i> (mice)
Furostanol	Insulinotropic effects (50)	<i>In vivo</i> (mice)

Glycosides

Glycosides are made up of the sugar moiety glycone (saccharide) and the non-sugar moiety aglycon (genin) linked by a glycosidic bond, derived from plant metabolism and attributed with different functions in living organisms, including storage purposes and playing defensive roles against pathogens and herbivores (57). The sugar moiety of glycosides contributes to the solubility, pharmacokinetics, and pharmacodynamic properties, while the non-sugar moiety contributes to the pharmacological effects. Glycosides in the plant are sometimes stored in inactive forms that can be easily transformed into active forms by cleavage to yield the desired. In contrast, in animals, glycosides facilitate the detoxification to remove poisons via binding to the sugar moiety of the glycosides (57). Glycosides are subdivided into four classes depending on the type of glycosidic bond and demonstrate several pharmacological and biological activities, including anti-inflammatory, antipyretic, anti-rheumatic, antimicrobial, and anti-diabetic activities (58). Several studies revealed the anti-diabetic effects of glycosides via a different mode of action to achieve glycemic control and alleviate pathological damages due to diabetes (59, 60).

Steviol glycosides and their metabolites demonstrated anti-diabetic effects in diabetic mice with increasing glucosyl groups in their molecules. This might be due to increased glucose uptake in the myocardium and brain and reduced glucose accumulation in the kidney and liver (61). In a similar study, glycosides from *Stevia rebaudiana* exhibited anti-diabetic properties exhibiting insulinotropic effects, thereby elevating glucose uptake and the number of glucose transporters (62). In vitro study on flavonol glycosides from *Cleome droserifolia* against diabetic enzymes revealed a moderate inhibition of α -amylase and α -glucosidase with a remarkably inhibited dipeptidyl peptidase IV (DPPIV) comparable to vildagliptin (63). Furthermore, the aldose reductase enzyme was inhibited, and oxidative stress was suppressed by the flavonol glycosides demonstrating protective action against diabetic complications. Triterpene glycosides from *Momordica charantia* exhibited anti-diabetic effects by inhibiting α -amylase and α -glucosidase comparable to acarbose (64). Moreover, these compounds inhibited the expression of pro-inflammatory markers and mitochondrial marker COX-2. Wedtrilosides A and B from *Wedelia trilobata* leaf demonstrated anti-diabetic effects by highly and moderately inhibiting the activity of α -glucosidase and α -amylase, respectively (65).

A flavonoid C-glycosides orientin dose-dependently inhibited the specificity of PTP1B in an in silico further subjection to in vitro study showed the inhibition was mixed, agreeing with the in silico study (66). Dietary supplementation with steviol glycosides normalized hyperlipidemia in STZ-induced diabetic rats with an effect on appetite and significant improvement in blood, liver, and kidney function indices with reduced tissue damage (67). However, there was no effect on blood glucose, insulin, insulin resistance, and antioxidant biomarkers. Flavone C-glycosides from *Beta vulgaris* demonstrated anti-diabetic potential by inhibiting α -glucosidase in vitro, thus a candidate for developing hypoglycemic drugs (68). Steviol glycoside from the aqueous extract of *Stevia rebaudiana* exhibited anti-diabetic potential in vitro by significantly inhibiting α -amylase comparable to the standard drug acarbose (69). In vitro study of glycoside fraction of *Gymnema sylvestre* using mouse pancreatic β -cell lines demonstrated a protective effect against H₂O₂ induced ROS generation with no toxicity on β -cell viability with a glucose dose-dependent insulinotropic effect comparable to glibenclamide and enhanced expression of GLUT2 (70).

Iridoid glycoside loganic acid reduced plasma biomarkers of carbonyl/oxidative stress in STZ-induced diabetic rats and increased the concentration of antioxidant enzymes with an accompanied decrease in the generation of intracellular reactive oxygen species (71). Additionally, loganic acid demonstrated a protective effect against the formation and accumulation of glycation and oxidation protein products and malondialdehyde derivatives in plasma. Total glycosides from *Cistanche tubulosa* exhibited anti-hyperglycemic and anti-hyperlipidemic activities in a combined STZ and diet-induced diabetes in rats by significantly reversing STZ-induced weight loss, reducing FBG and HbA_{1c} levels (72). Moreover, OGTT showed improvement in glucose tolerance, insulin sensitivity, and glycogen storage in the liver and muscles with glucose, a dose-dependent improvement in the activity of regulatory enzymes of carbohydrate metabolism and lipid profile, and antioxidant enzymes with a decrease in oxidative stress and inflammation serum markers (72). Total glycosides from okra fruit demonstrated anti-diabetic and antioxidant properties such as reduced levels of FBG, total cholesterol, triglycerides, and liver index,

accompanied by elevated oral glucose tolerance and superoxide dismutase in STZ-induced diabetic rats.

Additionally, an obvious recovery was found from a kidney lesion (73). Triterpenoid glycosides from *Cyclocarya paliurus* exhibited hypoglycemic activity by significantly increasing glucose utilization 3T3-L1 adipocyte, thus, might be the bioactive constituent associated with the traditional application of the plant in diabetic management (74). Figure 3 shows the structures of steviol and loganic acid.




Figure 3. Structures of steviol and loganic acid

Terpenoids

Terpenoids are groups of secondary metabolites, otherwise called isoprenoids, derived from five-carbon isoprene units, mostly originating from plants and animal sources with vast therapeutic applications against different diseases (75). They have diverse backbone structures and functional groups, differentiating them from each other and contributing to their diverse applications, such as flavoring agents, drugs, and nutraceuticals (75). Terpenoids have been attributed with several biological effects such as anti-inflammatory, antiparasitic, antibacterial, antiviral, antimalarial, antioxidant, antiaging, and anti-diabetic activities (75-78). Terpenoids affect their anti-diabetic activities by inhibiting insulin resistance developing enzymes, stabilizing PG, insulin levels, glucose metabolism, and antioxidant actions (79). Furthermore, they inhibit α -amylase, plasma lipase, α -glucosidase, tyrosine phosphatase, aldose reductase, and the expression of SGLT1, GLUT2, DPP4, PTP1B, DGAT, and HSD. Additionally, terpenoids promote the expression of GLUT4, GLP1, HSP, and adiponectin, and also activate PPAR- γ and incretins, and AMPK pathway while they inhibit inflammatory pathways, protein glycation, and formation of AGEs (79).

Terpenoids-rich extract from *Dillenia indica* exhibited anti-diabetic effects in insulin-resistant C2C12 cells and STZ-induced diabetic mice by reducing oxidative stress (80). The extract demonstrated positive effects in vitro using DPPH and ATBS and strongly inhibited α -glucosidase activity more than acarbose. Moreover, insulin receptor substrate-1 (INS-1) was stimulated, while expression of PDK1 and protein kinase B (Akt) were down-regulated (80). Furthermore, GLUT4 was translocated to the plasma membrane, and increased glucose absorption was observed with a significantly reduced level of ROS and elevated levels of antioxidant enzymes. Terpenoids were reported to activate AMP-activated protein kinase responsible for improving glucose homeostasis in the blood in insulin-resistant rodents, lipid profile, and blood pressure, thus a target for new anti-diabetic drugs (81).

Terpenoids-rich *Padina pavonia* extract exhibited anti-diabetic and antioxidant activities (82). The extract ameliorated hyperglycemia and dyslipidemia with accompanying improvement in insulin sensitivity and glucose tolerance in combined HFD- and STZ-induced diabetic rats. Moreover, there was an increase in the phosphorylation of glucose and glycogen formation with the suppression of gluconeogenic enzymes. Furthermore, the antioxidant capacity was improved, accompanied by up-regulated expression of the PPAR γ gene in the liver. Alzheimer-like alterations induced in diabetic rats were prevented by terpenoid-rich *Elettaria cardamomum* extract by inhibiting the activity of pro-inflammatory cytokines and GSK3 β and generation of ROS (83). Diabetes-induced loss in cognitive functions was reversed, and the increased acetylcholinesterase caspase-3 activity in the hippocampus was significantly lowered with decreased accumulation of the brain A β and p-tau. Moreover, the antioxidant defense system and expression of glutamate receptors were enhanced while hippocampal lipid peroxidation marker malondialdehyde was decreased.

Acyclic terpenoids from *Annona diversifolia* demonstrated in vitro hypoglycemic effects by inhibiting α -glucosidase and selectively inhibiting SGLT-1 in oral glucose, sucrose, lactose tolerance, and glucose excretion (84). Two non-polar terpenoids, betulinic acid, and stigmaterol, exhibited anti-diabetic activity with insulin mimic effects enhancing glucose uptake, significantly inducing and enhancing adipogenesis comparable to rosiglitazone (85). Terpenoid-rich extract of *Momordica charantia* highly inhibited the activity of α -glucosidase isolated from *Saccharomyces cerevisiae* in vitro with the Lineweaver-Burk plot showing a partially mixed-type inhibition which was

postulated to be the mode of action of the hypoglycemic effect of the plant (86). In another study, triterpenoids and flavonoid fractions of ethanol extract of *Canavalia* species exhibited significant anti-hyperglycemic and anti-hyperlipidemic effects in HFD and STZ-induced diabetic rats evidenced by the decreased HbA1C and blood glucose levels with improved lipid profile (87). The terpenoids cycloartenol and 24-methylene cycloartenol from *Ficus krishnae* exhibited a significant glucose-lowering effect in OGTT in HFD-STZ-induced type 2 diabetic rats (88). Additionally, in vitro study showed enhancement in the cell viability of RIN-5F cells, significantly protecting beta cells from glucose toxicity with enhanced insulin release.

Flavonoids

Flavonoids are low molecular weight polyphenolic compounds produced in secondary pathways synthesizing compounds required in trace amounts vastly found in plants and associated with various pharmacological and biological roles influencing different processes, notably in plants in response to environmental factors (89-91). Although flavonoids are mostly associated with antioxidant effects, other pharmacological effects include anti-inflammatory and antimicrobial effects (89). They are derived from 2-phenyl benzyl-pyrone derivatives through the phenylpropanoid pathway with a diphenyl propane backbone made up of 15-carbon atoms with two 6-membered rings attached to 3-carbon units, probably attached to the third ring structure (91). They are classified into different classes depending on the extent of oxidation of the second-ring and the third-ring carbon. Flavonoids were reported to be associated with different pharmacological properties against bacteria, viruses, inflammation, cancer, and oxidative stress, with the anti-diabetic and anti-inflammatory properties attributed to the C2-C3 double bond on the third ring and the hydroxyl groups at the C3', C4', C5, and C7 positions on the other rings (91, 92).

Hesperidin exhibited anti-inflammatory, anti-hypercholesterolemic effects in STZ-induced diabetic rats with a positive effect on hyperglycemia via the Klotho/FGF-23 pathway, which may also inhibit the rise AST, ALT, blood urea nitrogen, and creatinine levels (93). Naringenin demonstrated exerted dual agonistic anti-diabetic effect against PPAR γ /GLUT4, strongly regulating metabolism with the significant restoration of body weight, reduced blood glucose, normalized serum lipid profile, and hepatic and pancreatic oxidative stress biomarkers (94). Naringenin possesses anti-diabetic, antioxidant, and antiapoptotic with preventive effects against neurodegeneration of the retina observed in diabetic retinopathy in STZ-induced diabetic rats (95). Eriodictyol was reported to exhibit an insulinotropic effect in diabetic rats in a glucose-dependent manner via the cAMP/PKA pathway improving glucose tolerance and glycemic control (96). In another study, eriodictyol exerted protective effects against oxidative stress, inflammation, and apoptosis induced by hyperglycemia in the retinal ganglial cells of rats (97). The flavone apigenin effectively reduced intracellular ROS generation, DNA damage, and lipid peroxidation, relieved protein carbonylation, and reversed apoptosis induced by STZ in pancreatic β -cells in vitro (98). Moreover, apigenin regulates antioxidant defenses in pancreatic β -cells and is a free radical scavenger. Flavonoids ameliorate diabetic pathogenesis with its complications by regulating glucose metabolism and lipid profile coupled with regulation of the enzymes activities of liver enzymes through different mechanisms (99).

Quercetin was reported to exert type 2 diabetes preventive effects in the Chinese population due to an observed reduction in prevalence (100). Animal studies showed effectiveness at 10, 25, and 50 mg/kg of body weight of quercetin for its hypoglycemic effects (101). Combining quercetin with sitagliptin in STZ-induced diabetic rats improved metabolic profile, β -cell functions, and islet structure with increased SOD, GSH, and decreased NF- κ B (102). Rutin exhibits an anti-diabetic and protective effect against hyperglycemia and dyslipidemia via a reduction in intestinal absorption of carbohydrates, inhibition of gluconeogenesis, promote glucose uptake with accompanied insulinotropic effect and protective effects to the Langerhans islet against degeneration (103). Moreover, sorbitol formation, ROS generation, AGEs precursors, and inflammatory cytokines formation was diminished. Kaempferol significantly improved metabolism in STZ-induced diabetic mice by reducing glucose production and increasing its oxidation in the liver and muscles with no alteration in plasma insulin and glucagon levels (104). Kaempferol attenuated diabetic nephropathy in vitro via deactivation of RhoA induced by hyperglycemia and reduced pro-inflammatory cytokines expression, fibrosis, and oxidative stress in NRK-52E and RPTEC cells (105). Treating STZ-induced diabetic rats with fisetin alleviated hyperglycemia, hyperlipidemia, and heart function markers with accompanied minimized myocardium injury (106). Additionally, oxidative stress was suppressed by preventing inflammation and apoptosis and enhancing the antioxidant defenses of the heart.

Dietary luteolin supplementation to HFD-fed menopausal mice reduced adipose tissue inflammation and insulin resistance via suppression of M1-like macrophage polarization in the adipose tissue (107). The antioxidant potential of tangeretin was previously implicated in improving STZ-induced cellular apoptosis in INS-1 cells (108). Additionally, insulin secretion and insulin 1 and 2 expressions were improved with significantly increased antioxidant enzyme activities and decreased ROS generation. Diosmin exerted a hypoglycemic effect in STZ-induced diabetic rats with improved lipid profile by activating the imidazoline I-2 receptor, enhancing β -endorphin secretion and influencing

metabolic homeostasis (109). Baicalein increased glucose uptake and utilization with increased expression of insulin receptors and proteins and GLUT 2 in insulin-resistant HepG2 cells (110).

Furthermore, the expression of gluconeogenic enzymes was reduced by baicalein to improve glucose metabolism in the hepatocytes. In another study, baicalein was reported to exert protective effects in diabetic cardiomyopathy rats against oxidative stress and inflammation by promoting antioxidant enzymes activities and significantly reducing the level of malondialdehyde via the phosphatidylinositol 3-kinase/AKT pathway (111). Additionally, baicalein exhibited hepatoprotective effects in diabetic liver injury by suppressing the inflammatory cascade in diabetic mice, attenuating the expression of pro-inflammatory proteins, and inhibiting IL-1 β , IL-6, and TNF- α (112). Further study on palmitic acid-challenge human hepatic HepG2 cells showed baicalein reversal of the increased insulin, ALT, AST, TG, and TC levels (112). Table 3 summarizes some flavonoids' anti-diabetic effects, while their structures are shown in Figure 4.

Table 3. Antidiabetic flavonoids

Flavonoids	Anti-diabetic action	Effect
Hesperidin	Anti-inflammatory and anti-hypercholesterolemic (93)	<i>In vivo</i> (rats)
Naringenin	Anti-hyperglycemic, anti-hyperlipidemic, and antioxidant (94)	<i>In vivo</i> (rats)
Eriodictyol	Antioxidant and Insulinotropic effect (96)	<i>In vivo</i> and <i>In vitro</i>
Apigenin	Antioxidant and anti-inflammatory (98)	<i>In vitro</i>
Quercetin	Anti-hyperglycemic and antioxidant (102)	<i>In vivo</i> (rats)
Rutin	Anti-hyperglycemic, anti-inflammatory, and insulinotropic effects (10)	<i>In vivo</i> and <i>In vitro</i>
Kaempferol	Anti-hyperglycemic and anti-inflammatory (104)	<i>In vitro</i>
Fisetin	Anti-hyperglycemic and anti-hyperlipidemic (106)	<i>In vivo</i> (rats)
Luteolin	Anti-inflammatory (107)	<i>In vivo</i> (mice)
Baicalein	Anti-hyperglycemic, antioxidant, and anti-inflammatory (110-112)	<i>In vitro</i>




Figure 4. Structures of some antidiabetic flavonoids

Conclusion

Phytochemicals produced by plants as secondary metabolites play various pharmacological roles in diabetes especially considering the complications associated with persistent hyperglycemia. Although attaining glycemic control and treatment of diabetic complications remains a challenge, using different classes of phytochemicals from medicinal plants offers alternatives to achieving therapeutic goals. These phytochemicals act through different mechanisms of action in managing diabetic complications such as nephropathy, retinopathy, dyslipidemia, and poor glycemic control. Some therapeutic roles the phytochemicals play include attenuation of hyperglycemia and hyperlipidemia, α -glucosidase inhibition, insulin secretion regulation, and anti-inflammatory and antioxidant effects to repair tissue injuries. The various phytochemicals reviewed in the present study might provide a source for developing novel anti-diabetic agents.

Acknowledgments

Not applicable.

Funding source

The author declares no financial support was received for the research, authorship, and publication of this article.

Ethical statement

Not applicable.

Conflict of interest

The author declares no conflict of interest.

Author contributions

Muhammad Mubarak Dahiru wrote the article.

References

- ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Introduction and Methodology: Standards of Care in Diabetes—2023. *Diabetes Care*. 2023; 46(Suppl.1): S1-4. [View at Publisher] [Google Scholar] [DOI] [PMID]
- American Diabetes Association Professional Practice Committee. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022. *Diabetes Care*. 2022; 45(Suppl.1): S17-38. [View at Publisher] [Google Scholar] [DOI] [PMID]
- American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*. 2013;37(Supplement-1):S81-90. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract*. 2022;183:109119. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Dahiru MM, Nadro SM. A review of the Mechanisms of Action and Side Effects of Anti-diabetic Agents. *Trends in Pharmaceutical Sciences*. 2022;8(3):195-210. [View at Publisher] [Google Scholar] [DOI]
- Dahiru MM, Badgal EB, Musa N. Phytochemistry, GS-MS analysis, and heavy metals composition of aqueous and ethanol stem bark extracts of *Ximenia americana*. *GSC Biological and Pharmaceutical Sciences*. 2022;21(3):145-56. [View at Publisher] [Google Scholar] [DOI]
- Kurek J. editor. Introductory Chapter: Alkaloids - Their Importance in Nature and for Human Life. Rijeka: IntechOpen; 2019. p.Ch.1. [View at Publisher] [Google Scholar]
- Heinrich M, Mah J, Amirkia V. Alkaloids Used as Medicines: Structural Phytochemistry Meets Biodiversity—An Update and Forward Look. *Molecules*. 2021;26(7):1836. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Venkatesan GK, Kuppusamy A, Devarajan S, Kumar AKK. Review on medicinal potential of alkaloids and saponins. *Pharmacologyonline*. 2019;1:1-20. [View at Publisher] [Google Scholar]
- Aryal B, Raut BK, Bhattacharai S, Bhandari S, Tandan P, Gyawali K, et al. Potential Therapeutic Applications of Plant-Derived Alkaloids against Inflammatory and Neurodegenerative Diseases. *Evid Based Complement Alternat Med*. 2022;2022:1-18. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Behl T, Gupta A, Albratty M, Najmi A, Meraya AM, Alhazmi HA, et al. Alkaloidal Phytoconstituents for Diabetes Management: Exploring the Unrevealed Potential. *Molecules*. 2022;27(18):5851. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Mechanick JI, Marchetti A, Hegazi R, Hamdy O. Diabetes-Specific Nutrition Formulas in the Management of Patients with Diabetes and Cardiometabolic Risk. *Nutrients*. 2020;12(12):3616. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Azam K, Rasheed MA, Omer MO, Altaf I, Akhlaq A. Anti-hyperlipidemic and anti-diabetic evaluation of ethanolic leaf extract of *Catharanthus roseus* alone and in combination therapy. *Brazilian Journal of Pharmaceutical Sciences*. 2022;58. [View at Publisher] [Google Scholar] [DOI]
- Ge Q, Chen L, Yuan Y, Liu L, Feng F, Lv P, et al. Network pharmacology-based dissection of the anti-diabetic mechanism of *Lobelia chinensis*. *Front Pharmacol*. 2020;11:347. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Dell'Orman Orhan D, Orhan N, Demir Ö, Konuklugül B. In Vitro Antidiabetic and Antioxidant Effects of Thirteen Marine Organisms From

- Mediterranean Sea. *Farmacía*. 2021;69(1):68-74. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
16. Hassan SS, Muhammad I, Abbas SQ, Hassan M, Majid M, Jin HZ, et al. Stress driven discovery of natural products from actinobacteria with anti-oxidant and cytotoxic activities including docking and admet properties. *Int J Mol Sci*. 2021;22(21):11432. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 17. Uvarani C, Jaivel N, Sankaran M, Chandraprakash K, Ata A, Mohan PS. Axially chiral bis-carbazoles and biological evaluation of the constituents from *Murraya koenigii*. *Fitoterapia*. 2014;94:10-20. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 18. Tiong SH, Looi CY, Arya A, Wong WF, Hazni H, Mustafa MR, et al. Vindogentanine, a hypoglycemic alkaloid from *Catharanthus roseus* (L.) G. Don (Apocynaceae). *Fitoterapia*. 2015;102:182-8. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 19. Jan NU, Ali A, Ahmad B, Iqbal N, Adhikari A, Ali A, et al. Evaluation of antidiabetic potential of steroidal alkaloid of *Sarcococca saligna*. *Biomedicine and Pharmacotherapy*. 2018;100:461-6. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 20. Patel OPS, Mishra A, Maurya R, Saini D, Pandey J, Taneja I, et al. Naturally occurring carbazole alkaloids from *Murraya koenigii* as potential antidiabetic agents. *Journal of Natural Products*. 2016;79(5):1276-84. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 21. Patel MB, Mishra S. Isoquinoline alkaloids from *Tinospora cordifolia* inhibit rat lens aldose reductase. *Phytotherapy Research*. 2012;26(9):1342-7. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 22. Cho H. Protein tyrosine phosphatase 1B (PTP1B) and obesity. *Vitamins and Hormones*. 2013;91:405-24. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 23. Lankatillake C, Huynh T, Dias DA. Understanding glycaemic control and current approaches for screening antidiabetic natural products from evidence-based medicinal plants. *Plant Methods*. 2019;15(1):1-35. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 24. Wiedemann M, Gurrola-Díaz CM, Vargas-Guerrero B, Wink M, García-López PM, Difer M. Lupanine improves glucose homeostasis by influencing KATP channels and insulin gene expression. *Molecules*. 2015;20(10):19085-100. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 25. Subramanian SP, Prasath GS. Antidiabetic and antidyslipidemic nature of trigonelline, a major alkaloid of fenugreek seeds studied in high-fat-fed and low-dose streptozotocin-induced experimental diabetic rats. *Biomedicine & Preventive Nutrition*. 2014;4(4):475-80. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 26. Freitas Ld, Valli M, Dametto AC, Pennacchi PC, Andricopulo AD, Maria-Engler SS, et al. Advanced glycation end product inhibition by alkaloids from *Ocotea paranapiacabensis* for the prevention of skin aging. *Journal of Natural Products*. 2020;83(3):649-56. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 27. Ye G, Huang C, Li J, Chen T, Tang J, Liu W, et al. Isolation, Structural Characterization and Antidiabetic Activity of New Diketopiperazine Alkaloids from Mangrove Endophytic Fungus *Aspergillus* sp. 16-5c. *Marine Drugs* [Internet]. 2021; 19(7). [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 28. Li C-J, Chen P-N, Li H-J, Mahmud T, Wu D-L, Xu J, et al. Potential Antidiabetic Fumiquinazoline Alkaloids from the Marine-Derived Fungus *Scedosporium apiospermum* F41-1. *Journal of Natural Products*. 2020;83(4):1082-91. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 29. Zhang H, Hui J, Yang J, Deng J, Fan D. Eurocrystatine, a plant alkaloid from *Eurotium cristatum*, alleviates insulin resistance in db/db diabetic mice via activation of PI3K/AKT signaling pathway. *European Journal of Pharmacology*. 2020;887:173557. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 30. Bai J, Zhang S, Cao J, Sun H, Mang Z, Shen WL, et al. Hernandezine, a natural herbal alkaloid, ameliorates type 2 diabetes by activating AMPK in two mouse models. *Phytochemistry*. 2022;105:154366. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 31. Dou Y, Huang R, Li Q, Liu Y, Li Y, Chen H, et al. Oxyberberine, an absorbed metabolite of berberine, possess superior hypoglycemic effect via regulating the PI3K/Akt and Nrf2 signaling pathways. *Biomedicine and Pharmacotherapy*. 2021;137:111312. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 32. Zang Y. Pharmacological Activities of Coumarin Compounds in Licorice: A Review. *Natural Product Communications*. 2020;15(9):1934578X20953954. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 33. Yang Y, Laval S, Yu B. Chapter Two - Chemical Synthesis of Saponins. In: Baker DC, editor. *Advances in Carbohydrate Chemistry and Biochemistry*. 79: Academic Press; 2021. p. 63-150. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 34. Amraei S, Ahmadi S. Recent studies on antimicrobial and anticancer activities of saponins: A mini-review. *Nano Micro Biosystems*. 2022;1(1):22-6. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 35. Kareem O, Ali T, Dar LA, Mir SA, Rashid R, Nazli N, et al. Positive Health Benefits of Saponins from Edible Legumes: Phytochemistry and Pharmacology. *Edible Plants in Health and Diseases*. 2022:279-98. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 36. Ashour A, Abed El Aziz M, Melad A. A review on saponins from medicinal plants: chemistry, isolation, and determination. *Journal of Nanomedicine Research*. 2019;7:282-8. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 37. Choudhary N, Khatik LG, Suttee A. The Possible Role of Saponin in Type-II Diabetes- A Review. *Current Diabetes Reviews*. 2021;17(2):107-21. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 38. Zhou Y, Xu B. New insights into anti-diabetes effects and molecular mechanisms of dietary saponins. *Critical Reviews in Food Science and Nutrition*. 2022:1-26. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 39. Jiang S, Xu L, Xu Y, Guo Y, Wei L, Li X, et al. Antidiabetic effect of *Momordica charantia* saponins in rats induced by high-fat diet combined with STZ. *Electronic Journal of Biotechnology*. 2020;43:41-7. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 40. 4Keller AC, He K, Brillantes A-M, Kennelly EJ. A characterized saponin-rich fraction of *Momordica charantia* shows antidiabetic activity in C57BLK/6 mice fed a high fat diet. *Phytomedicine Plus*. 2021;1(4):100134. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 41. Ejelonu OC, Elekofehinti OO, Adanlawo IG, Kundu R. TGR5 potentiates GLP-1 secretion and cause pancreatic islet regeneration in response to *Tithonia diversifolia* saponin-rich extract in diabetic model mice. *Phytomedicine Plus*. 2022;2(1):100203. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 42. An S, Niu D, Wang T, Han B, He C, Yang X, et al. Total Saponins Isolated from Corni Fructus via Ultrasonic Microwave-Assisted Extraction Attenuate Diabetes in Mice. *Foods* [Internet]. 2021;10(3). [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 43. Parveen A, Farooq MA, Kyunn WW. A New Oleanane Type Saponin from the Aerial Parts of *Nigella sativa* with Anti-Oxidant and Anti-Diabetic Potential. *Molecules* [Internet]. 2020;25(9). [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 44. Samaddar S, Jha DK, Koneri R. Optimization of pancreatic islet isolation from rat and evaluation of islet protective potential of a saponin isolated from fruits of *Momordica dioica*. *Journal of Applied Pharmaceutical Science*. 2020;10(7):089-99. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 45. Wang Q, Wu X, Shi F, Liu Y. Comparison of antidiabetic effects of saponins and polysaccharides from *Momordica charantia* L. in STZ-induced type 2 diabetic mice. *Biomedicine and Pharmacotherapy*. 2019;109:744-50. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 46. Kamal R, Kharbach M, Heyden YV, Yu H, Bouklouze A, Cherrah Y, et al. In Vitro & In Vivo Anti-Hyperglycemic Potential of Saponins Cake and Argan Oil from *Argania spinosa*. *Foods* [Internet]. 2021;10(5). [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 47. Boussoussa H, Khacheba I, Berramdane T, Maamri A, Bendahgane H, Yousfi M. In vitro antidiabetic effect of saponins and phenolic extracts from fruits and seeds of Algerian cypress tree: *Cupressus sempervirens* L. *Current Enzyme Inhibition*. 2018;14(2):92-6. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 48. Lundqvist LCE, Rattigan D, Ehtesham E, Demmou C, Östenson C-G, Sandström C. Profiling and activity screening of Dammarane-type triterpen saponins from *Gynostemma pentaphyllum* with glucose-dependent insulin secretory activity. *Scientific Reports*. 2019;9(1):627. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 49. Xiong H, Zhang S, Zhao Z, Zhao P, Chen L, Mei Z. Antidiabetic activities of entagenic acid in type 2 diabetic db/db mice and L6 myotubes via AMPK/GLUT4 pathway. *Journal of Ethnopharmacology*. 2018;211:366-74. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 50. Pandey AR, Ahmad S, Singh SP, Mishra A, Bisen AC, Sharma G, et al. Furostanol saponins from *Asparagus racemosus* as potential hypoglycemic agents. *Phytochemistry*. 2022;201:113286. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 51. Al Sharif M, Alov P, Diukendjieva A, Vitcheva V, Simeonova R, Krasteva I, et al. Molecular determinants of PPAR γ partial agonism and related in silico/in vivo studies of natural saponins as potential type 2 diabetes modulators. *Food and Chemical Toxicology*. 2018;112:47-59. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 52. Salah El Dine R, Abdallah HM, Kandil ZA, Zaki AA, Khan SI, Khan IA. PPAR α and γ Activation Effects of New Nor-triterpenoidal Saponins from the Aerial Parts of *Anabasis articulata*. *Planta Medica*. 2019;85(04):274-81. Epub 10/25. En. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
 53. Dubey K, Dubey R, Gupta RA, Gupta AK. Anti-diabetic and antioxidant potential of saponin extract of leaves of *Ziziphus mauritiana*. *Journal of*

- Drug Delivery and Therapeutics. 2019;9(2-A):75-7. [View at Publisher] [Google Scholar] [DOI] [PMID]
54. Chai Y, Luo J, Bao Y. Effects of Polygonatum sibiricum saponin on hyperglycemia, gut microbiota composition and metabolic profiles in type 2 diabetes mice. Biomedicine and Pharmacotherapy. 2021;143:112155. [View at Publisher] [Google Scholar] [DOI] [PMID]
 55. Zhu X, Li C, Zhu Y. Saponins extracted from Asparagus officinalis L. by products exerts hypoglycemic effect in streptozotocin induced type 2 diabetic rats. IOP Conference Series: Earth and Environmental Science. 2020;559(1):012002. [View at Publisher] [Google Scholar] [DOI] [PMID]
 56. Guo X, Sun W, Luo G, Wu L, Xu G, Hou D, et al. Panax notoginseng saponins alleviate skeletal muscle insulin resistance by regulating the IRS1–PI3K–AKT signaling pathway and GLUT4 expression. FEBS Open Bio. 2019;9(5):1008-19. [View at Publisher] [Google Scholar] [DOI] [PMID]
 57. Gangasani JK, Pemmaraju DB, Murthy USN, Rengan AK, Naidu VGM. Chapter 4 - Chemistry of herbal biomolecules. In: Mandal SC, Nayak AK, Dhara AK, editors. Herbal Biomolecules in Healthcare Applications: Academic Press; 2022. p.63-79. [View at Publisher] [Google Scholar] [DOI] [PMID]
 58. Bartnik M, Facey PC. Chapter 8 - Glycosides. In: Badal S, Delgoda R, editors. Pharmacognosy. Boston: Academic Press; 2017. p.101-61. [View at Publisher] [Google Scholar] [DOI] [PMID]
 59. Pałasz A, Cież D, Trzewik B, Miszczak K, Tynor G, Bazan B. In the Search of Glycoside-Based Molecules as Antidiabetic Agents. Topics in Current Chemistry. 2019;377(4):19. [View at Publisher] [Google Scholar] [DOI] [PMID]
 60. Salehi B, Ata A, V. Anil Kumar N, Sharopov F, Ramirez-Alarcon K, Ruiz-Ortega A, et al. Antidiabetic potential of medicinal plants and their active components. Biomolecules. 2019;9(10):551. [View at Publisher] [Google Scholar] [DOI] [PMID]
 61. Myint KZ, Chen J-m, Zhou Z-y, Xia Y-m, Lin J, Zhang J. Structural dependence of antidiabetic effect of steviol glycosides and their metabolites on streptozotocin-induced diabetic mice. Journal of the Science of Food and Agriculture. 2020;100(10):3841-9. [View at Publisher] [Google Scholar] [DOI] [PMID]
 62. Kurek JM, Krejpcio Z. The functional and health-promoting properties of Stevia rebaudiana Bertoni and its glycosides with special focus on the antidiabetic potential – A review. Journal of Functional Foods. 2019;61:103465. [View at Publisher] [Google Scholar] [DOI] [PMID]
 63. Abdel Motaal A, Salem HH, Almaghaslah D, Alsayari A, Bin Muhsinah A, Alfaifi MY, et al. Flavonol Glycosides: In Vitro Inhibition of DPPIV, Aldose Reductase and Combating Oxidative Stress are Potential Mechanisms for Mediating the Antidiabetic Activity of Cleome droserifolia. Molecules [Internet]. 2020;25(24). [View at Publisher] [Google Scholar] [DOI] [PMID]
 64. Perera WH, Shivanagoudra SR, Pérez JL, Kim DM, Sun Y, K. Jayaprakasha G, et al. Anti-Inflammatory, Antidiabetic Properties and In Silico Modeling of Cucurbitane-Type Triterpene Glycosides from Fruits of an Indian Cultivar of Momordica charantia L. Molecules [Internet]. 2021; 26(4). [View at Publisher] [Google Scholar] [DOI] [PMID]
 65. Luyen NT, Binh PT, Tham PT, Hung TM, Dang NH, Dat NT, et al. Wedrilosides A and B, two new diterpenoid glycosides from the leaves of Wedelia trilobata (L.) Hitchc. with α -amylase and α -glucosidase inhibitory activities. Bioorganic Chemistry. 2019;85:319-24. [View at Publisher] [Google Scholar] [DOI] [PMID]
 66. Rampadarath A, Balogun FO, Pillay C, Sabiu S. Identification of Flavonoid C-Glycosides as Promising Antidiabetics Targeting Protein Tyrosine Phosphatase 1B. Journal of Diabetes Research. 2022;2022:6233217. [View at Publisher] [Google Scholar] [DOI] [PMID]
 67. Kurek JM, Król E, Krejpcio Z. Steviol Glycosides Supplementation Affects Lipid Metabolism in High-Fat Fed STZ-Induced Diabetic Rats. Nutrients [Internet]. 2021;13(1). [View at Publisher] [Google Scholar] [DOI] [PMID]
 68. Mohammed HS, Abdel-Aziz MM, Abu-Baker MS, Saad AM, Mohamed MA, Ghareeb MA. Antibacterial and potential antidiabetic activities of flavone C-glycosides isolated from Beta vulgaris subspecies cicla L. var. flavescens (Amaranthaceae) cultivated in Egypt. Current Pharmaceutical Biotechnology. 2019;20(7):595-604. [View at Publisher] [Google Scholar] [DOI] [PMID]
 69. Zaidan UH, Mohamad Zen NI, Amran NA, Shamsi S, Gani SSA. Biochemical evaluation of phenolic compounds and steviol glycoside from Stevia rebaudiana extracts associated with in vitro antidiabetic potential. Biocatalysis and Agricultural Biotechnology. 2019;18:101049. [View at Publisher] [Google Scholar] [DOI] [PMID]
 70. Shenoy RS, Prashanth KVH, Manonmani HK. <i>In Vitro</i> Antidiabetic Effects of Isolated Triterpene Glycoside Fraction from <i>Gymnema sylvestre</i>. Evidence-Based Complementary and Alternative Medicine. 2018;2018:7154702. [View at Publisher] [Google Scholar] [DOI] [PMID]
 71. Dzydzan O, Brodyak I, Sokół-Łętowska A, Kucharska AZ, Sybirna N. Loganic Acid, an Iridoid Glycoside Extracted from Cornus mas L. Fruits, Reduces of Carbonyl/Oxidative Stress Biomarkers in Plasma and Restores Antioxidant Balance in Leukocytes of Rats with Streptozotocin-Induced Diabetes Mellitus. Life [Internet]. 2020;10(12). [View at Publisher] [Google Scholar] [DOI] [PMID]
 72. Zhu K, Meng Z, Tian Y, Gu R, Xu Z, Fang H, et al. Hypoglycemic and hypolipidemic effects of total glycosides of Cistanche tubulosa in diet/streptozotocin-induced diabetic rats. Journal of Ethnopharmacology. 2021;276:113991. [View at Publisher] [Google Scholar] [DOI] [PMID]
 73. Huang Z-Y, Jia S-S, Jia A, Huang J-W, Yuan K. Antidiabetic potential of the total flavone glycoside from okra fruit in type 2 diabetic rats. Pharmacognosy Magazine. 2018;14(58):482-8. [View at Publisher] [Google Scholar] [DOI] [PMID]
 74. Sun H, Tan J, Lv W, Li J, Wu J, Xu J, et al. Hypoglycemic triterpenoid glycosides from Cyclocarya paliurus (Sweet Tea Tree). Bioorganic Chemistry. 2020;95:103493. [View at Publisher] [Google Scholar] [DOI] [PMID]
 75. Isah MB, Tajuddeen N, Umar MI, Alhafiz ZA, Mohammed A, Ibrahim MA. Chapter 7 - Terpenoids as Emerging Therapeutic Agents: Cellular Targets and Mechanisms of Action against Protozoan Parasites. In: Atta ur R, editor. Studies in Natural Products Chemistry. 59: Elsevier; 2018. p. 227-50. [View at Publisher] [Google Scholar] [DOI] [PMID]
 76. Yang W, Chen X, Li Y, Guo S, Wang Z, Yu X. Advances in Pharmacological Activities of Terpenoids. Natural Product Communications. 2020;15(3):1934578X20903555. [View at Publisher] [Google Scholar] [DOI] [PMID]
 77. Kim T, Song B, Cho KS, Lee I-S. Therapeutic potential of volatile terpenes and terpenoids from forests for inflammatory diseases. International journal of molecular sciences. 2020;21(6):2187. [View at Publisher] [Google Scholar] [DOI] [PMID]
 78. Deepak Kumar D, Chandra Kishore T, Anil Kumar S, Vaibhav T. Revisiting the Medicinal Value of Terpenes and Terpenoids. In: Vijay Singh M, Hanuman Prasad P, Sunita Kumari M, editors. Revisiting Plant Biostimulants. Rijeka: IntechOpen; 2022. p.Ch.5. [View at Publisher] [Google Scholar] [DOI] [PMID]
 79. Putta DS, Yarla Ns, Kilari E, Surekha C, Aliev G, Basavaraju D, et al. Therapeutic Potentials of Triterpenes in Diabetes and its Associated Complications. Current Topics in Medicinal Chemistry. 2016;16:Epup ahead of print. [View at Publisher] [Google Scholar] [DOI] [PMID]
 80. Song B-R, Alam MB, Lee S-H. Terpenoid-Rich Extract of Dillenia indica L. Bark Displays Antidiabetic Action in Insulin-Resistant C2C12 Cells and STZ-Induced Diabetic Mice by Attenuation of Oxidative Stress. Antioxidants [Internet]. 2022;11(7). [View at Publisher] [Google Scholar] [DOI] [PMID]
 81. SmithaGrace SR, Chandran G, Chauhan JB. Terpenoids: An Activator of "Fuel-Sensing Enzyme AMPK" with Special Emphasis on Antidiabetic Activity. In: Ozturk M, Hakeem KR, editors. Plant and Human Health, Volume 2: Phytochemistry and Molecular Aspects. Cham: Springer International Publishing; 2019. p.227-44. [View at Publisher] [Google Scholar] [DOI] [PMID]
 82. Germoush MO, Elgebaly HA, Hassan S, Kamel EM, Bin-Jumah M, Mahmoud AM. Consumption of Terpenoids-Rich Padina pavonia Extract Attenuates Hyperglycemia, Insulin Resistance and Oxidative Stress, and Upregulates PPAR γ in a Rat Model of Type 2 Diabetes. Antioxidants [Internet]. 2020; 9(1). [View at Publisher] [Google Scholar] [DOI] [PMID]
 83. Gomaa AA, Makkoul RM, El-Mokhtar MA, Abdel-Rahman EA, Ahmed IA, Nicola MA. Terpenoid-rich Elettaria cardamomum extract prevents Alzheimer-like alterations induced in diabetic rats via inhibition of GSK3 β activity, oxidative stress and pro-inflammatory cytokines. Cytokine. 2019;113:405-16. [View at Publisher] [Google Scholar] [DOI] [PMID]
 84. Valdés M, Calzada F, Mendieta-Wejbe JE, Merlín-Lucas V, Velázquez C, Barbosa E. Antihyperglycemic Effects of Annona diversifolia Safford and Its Acyclic Terpenoids: α -Glucosidase and Selective SGLT1 Inhibitors. Molecules [Internet]. 2020;25(15). [View at Publisher] [Google Scholar] [DOI] [PMID]
 85. Ahmed QU, Hasan M, Siddiqui MJ. ID 82. In vitro Adipogenic Potential and Glucose Uptake Stimulatory Effect of the Terpenoids Isolated from Tetracera indica Merr. Journal of Pharmacy & Bioallied Sciences. 2020;12. [View at Publisher] [Google Scholar] [DOI] [PMID]
 86. Sallau AB, Yakubu RN, Abdullahi SM, Salihu A, Boniface BY. In vitro effect of terpenoids - rich extract of momordica charantia on alpha glucosidase activity. Vitae. 2018;25:148-53. [View at Publisher] [Google Scholar] [DOI] [PMID]
 87. Anitha K, Mohana Lakshmi S, Satyanarayana SV. Antidiabetic, lipid lowering and antioxidant potentiating effect of Canavalia species in high fat diet-streptozotocin induced model. Advances in Traditional Medicine. 2020;20(4):609-18. [View at Publisher] [Google Scholar] [DOI] [PMID]
 88. 88.Nair ANS, Nair RVR, Nair APR, Nair AS, Thyagarajan S, Johnson AJ, et al. Antidiabetes constituents, cycloartenol and 24-methylenecycloartanol, from Ficus krishnae. PloS One. 2020;15(6):e0235221. [View at Publisher] [Google Scholar] [DOI] [PMID]
 89. Shen N, Wang T, Gan Q, Liu S, Wang L, Jin B. Plant flavonoids: Classification, distribution, biosynthesis, and antioxidant activity. Food

- Chemistry. 2022;383:132531. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
90. Donadio G, Mensitieri F, Santoro V, Parisi V, Bellone ML, De Tommasi N, et al. Interactions with microbial proteins driving the antibacterial activity of flavonoids. *Pharmaceutics*. 2021;13(5):660. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
91. Roy A, Datta S, Bhatia KS, Jha P, Prasad R. Role of plant derived bioactive compounds against cancer. *South African Journal of Botany*. 2021. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
92. Shamsudin NF, Ahmed QU, Mahmood S, Shah SA, Sarian MN, Khattak MM, et al. Flavonoids as Antidiabetic and Anti-Inflammatory Agents: A Review on Structural Activity Relationship-Based Studies and Meta-Analysis. *International Journal of Molecular Sciences* [Internet]. 2022; 23(20). [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
93. Dokumacioglu E, Iskender H, Musmul A. Effect of hesperidin treatment on α -Klotho/FGF-23 pathway in rats with experimentally-induced diabetes. *Biomedicine and Pharmacotherapy*. 2019;109:1206-10. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
94. Singh AK, Raj V, Keshari AK, Rai A, Kumar P, Rawat A, et al. Isolated mangiferin and naringenin exert antidiabetic effect via PPAR γ /GLUT4 dual agonistic action with strong metabolic regulation. *Chemico-Biological Interactions*. 2018;280:33-44. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
95. Al-Dosari DI, Ahmed MM, Al-Rejaie SS, Alhomida AS, Ola MS. Flavonoid Naringenin Attenuates Oxidative Stress, Apoptosis and Improves Neurotrophic Effects in the Diabetic Rat Retina. *Nutrients* [Internet]. 2017;9(10). [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
96. Hameed A, Hafizur RM, Hussain N, Raza SA, Rehman M, Ashraf S, et al. Eriodictyol stimulates insulin secretion through cAMP/PKA signaling pathway in mice islets. *European Journal of Pharmacology*. 2018;820:245-55. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
97. Lv P, Yu J, Xu X, Lu T, Xu F. Eriodictyol inhibits high glucose-induced oxidative stress and inflammation in retinal ganglial cells. *Journal of Cellular Biochemistry*. 2019;120(4):5644-51. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
98. Wang N, Yi WJ, Tan L, Zhang JH, Xu J, Chen Y, et al. Apigenin attenuates streptozotocin-induced pancreatic β cell damage by its protective effects on cellular antioxidant defense. *In Vitro Cellular & Developmental Biology - Animal*. 2017;53(6):554-63. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
99. Al-Ishaq RK, Abotaleb M, Kubatka P, Kajo K, Büsselberg D. Flavonoids and Their Anti-Diabetic Effects: Cellular Mechanisms and Effects to Improve Blood Sugar Levels. *Biomolecules* [Internet]. 2019;9(9). [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
100. Yao Z, Gu Y, Zhang Q, Liu L, Meng G, Wu H, et al. Estimated daily quercetin intake and association with the prevalence of type 2 diabetes mellitus in Chinese adults. *European Journal of Nutrition*. 2019;58(2):819-30. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
101. Bule M, Abdurahman A, Nikfar S, Abdollahi M, Amini M. Antidiabetic effect of quercetin: A systematic review and meta-analysis of animal studies. *Food and Chemical Toxicology*. 2019;125:494-502. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
102. Eitah HE, Maklad YA, Abdelkader NF, Gamal el Din AA, Badawi MA, Kenawy SA. Modulating impacts of quercetin/sitagliptin combination on streptozotocin-induced diabetes mellitus in rats. *Toxicology and Applied Pharmacology*. 2019;365:30-40. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
103. Ghorbani A. Mechanisms of antidiabetic effects of flavonoid rutin. *Biomedicine and Pharmacotherapy*. 2017;96:305-12. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
104. Alkhalidi H, Moore W, Wang Y, Luo J, McMillan RP, Zhen W, et al. The Flavonoid Kaempferol Ameliorates Streptozotocin-Induced Diabetes by Suppressing Hepatic Glucose Production. *Molecules* [Internet]. 2018; 23(9). [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
105. Sharma D, Gondaliya P, Tiwari V, Kalia K. Kaempferol attenuates diabetic nephropathy by inhibiting RhoA/Rho-kinase mediated inflammatory signalling. *Biomedicine and Pharmacotherapy*. 2019;109:1610-9. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
106. Althunibat OY, Al Hroob AM, Abukhalil MH, Germoush MO, Bin-Jumah M, Mahmoud AM. Fisetin ameliorates oxidative stress, inflammation and apoptosis in diabetic cardiomyopathy. *Life Sciences*. 2019;221:83-92. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
107. Baek Y, Lee MN, Wu D, Pae M. Luteolin Improves Insulin Resistance in Postmenopausal Obese Mice by Altering Macrophage Polarization (FS12-01-19). *Current Developments in Nutrition*. 2019;3(Supplement_1):nzz049.FS012-001-019. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
108. Liu Y, Han J, Zhou Z, Li D. Tangeretin inhibits streptozotocin-induced cell apoptosis via regulating NF- κ B pathway in INS-1 cells. *Journal of Cellular Biochemistry*. 2019;120(3):3286-93. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
109. Hsu C-C, Lin MH, Cheng J-T, Wu MC. Diosmin, a Citrus Nutrient, Activates Imidazoline Receptors to Alleviate Blood Glucose and Lipids in Type 1-Like Diabetic Rats. *Nutrients* [Internet]. 2017;9(7). [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
110. Yang Z, Huang W, Zhang J, Xie M, Wang X. Baicalein improves glucose metabolism in insulin resistant HepG2 cells. *European Journal of Pharmacology*. 2019;854:187-93. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
111. Ma L, Li XP, Ji HS, Liu YF, Li EZ. Baicalein protects rats with diabetic cardiomyopathy against oxidative stress and inflammation injury via phosphatidylinositol 3-kinase (PI3K)/AKT pathway. *Medical science monitor: international medical journal of experimental and clinical research*. 2018;24:5368. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
112. Yin H, Huang L, Ouyang T, Chen L. Baicalein improves liver inflammation in diabetic db/db mice by regulating HMGB1/TLR4/NF- κ B signaling pathway. *International Immunopharmacology*. 2018;55:55-62. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
113. Chattopadhyay RR. A comparative evaluation of some blood sugar lowering agents of plant origin. *Journal of ethnopharmacology*. 1999 Nov 30;67(3):367-72. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]
114. Yao XG, Chen F, Li P, Quan L, Chen J, Yu L, Ding H, Li C, Chen L, Gao Z, Wan P. Natural product vindoline stimulates insulin secretion and efficiently ameliorates glucose homeostasis in diabetic murine models. *Journal of ethnopharmacology*. 2013 Oct 28;150(1):285-97. [[View at Publisher](#)] [[Google Scholar](#)] [[DOI](#)] [[PMID](#)]

How to Cite:

Dahiru MM. Recent advances in the therapeutic potential phytochemicals in managing diabetes. *JCBR*. 2023;7(1):13-20.



© The author(s)